Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN98667 | Santamarine Santamarine has significant anticancer activity, can inhibit L1210 cells because of its cytotoxic,cytostatic and blocking mitosis and reducing uptake of thymidine. Santamarine and reynosin show bactericidal activity against clinical strains of Mycobacterium tuberculosis. |
| CFN98669 | Crategolic acid Crategolic acid(Maslinic acid) has neuroprotective, anti-inflammatory, anti- osteoporosis, cytotoxic and antiviral activities, it suppresses RANKL-induced osteoclastogenesis through NF-κB and MAPK/AP-1 signaling pathways , and has beneficial effects on hypoxic neurons by suppressing iNOS activation.Crategolic acid as a feed additive to stimulate growth and hepatic protein-turnover rates in rainbow trout ( Onchorhynchus mykiss ). |
| CFN98670 | Genkwanin Genkwanin has antitumor, and anti-inflammatory activities, it enhances host immunity, decreases the inflammatory cytokine levels, and regulates the miR-101/MKP-1/MAPK pathway.Genkwanin may have anti-skin ageing activity, it can up-regulate the transcriptional activation of human type vii collagen gene promoter, stimulating the formation of anchoring fibrils at the basement membrane zone in skin contributed to preventing skin ageing; it also induces a decrease of melanin synthesis by inhibiting tyrosinase activity, it could as skin whitening agent in cosmetic preparations. |
| CFN90012 | Sorafenib Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC. The combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials. |
| CFN90015 | Dasatinib monohydrate Dasatinib monohydrate is a selective protein tyrosine kinase inhibitor with immunomodulatory properties that abrogates multiple signal transduction pathways in immune cells, it may be used to treat multiple sclerosis. Dasatinib is a 2-aminothiazole-derived inhibitor of Src family kinases, inhibits c-Abl and Bcr-Abl tyrosine kinase activity and shows efficacy against imatinib-resistant Bcr-Abl mutations. Combined treatment with bortezomib plus Dasatinib monohydrate caused cell cycle arrest in the G1 phase through inactivation of PDGFRβ and promoted bortezomib-induced apoptosis in GIST-T1 cells. Dasatinib monohydrate monotherapy demonstrates anti‑ovarian cancer activities. The effects of Dasatinib monohydrate and paclitaxel treatments on ovarian cancer cells appeared to be mediated by the Src pathway. |
